Artikler med mandater om offentlig tilgang - Kristin Bamber HighlandLes mer
Ikke tilgjengelig noe sted: 1
Clinical profile of anti-PL-12 autoantibody: cohort study and review of the literature
M Kalluri, SA Sahn, CV Oddis, SL Gharib, L Christopher-Stine, SK Danoff, ...
Chest 135 (6), 1550-1556, 2009
Mandater: US National Institutes of Health
Tilgjengelige et eller annet sted: 27
Nintedanib for systemic sclerosis–associated interstitial lung disease
O Distler, KB Highland, M Gahlemann, A Azuma, A Fischer, MD Mayes, ...
New England Journal of Medicine 380 (26), 2518-2528, 2019
Mandater: National Institute for Health Research, UK
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial
DP Tashkin, MD Roth, PJ Clements, DE Furst, D Khanna, EC Kleerup, ...
The lancet Respiratory medicine 4 (9), 708-719, 2016
Mandater: US National Institutes of Health
Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial
KB Highland, O Distler, M Kuwana, Y Allanore, S Assassi, A Azuma, ...
The Lancet Respiratory Medicine 9 (1), 96-106, 2021
Mandater: National Institute of Health and Medical Research, France
Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
LA Saketkoo, S Mittoo, D Huscher, D Khanna, PF Dellaripa, O Distler, ...
Thorax 69 (5), 436-444, 2014
Mandater: US National Institutes of Health, Versus Arthritis, UK, UK Medical Research …
Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial
S Farha, D Saygin, MM Park, HI Cheong, K Asosingh, SAA Comhair, ...
JCI insight 2 (16), 2017
Mandater: US National Institutes of Health
Treatment of Systemic Sclerosis–associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline
G Raghu, SB Montesi, RM Silver, T Hossain, M Macrea, D Herman, ...
American Journal of Respiratory and Critical Care Medicine, 2023
Mandater: US Department of Defense, US National Institutes of Health, US Department of …
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
JR Seibold, TM Maher, KB Highland, S Assassi, A Azuma, LK Hummers, ...
Annals of the rheumatic diseases 79 (11), 1478-1484, 2020
Mandater: US National Institutes of Health
Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical …
RP Baughman, KC Meyer, I Nathanson, L Angel, SM Bhorade, KM Chan, ...
Chest 142 (5), e1S-e111S, 2012
Mandater: US National Institutes of Health
Microvascular involvement in systemic sclerosis and systemic lupus erythematosus
D Saygin, KB Highland, AR Tonelli
Microcirculation 26 (3), e12440, 2019
Mandater: US National Institutes of Health
Clinical characteristics and transplant-free survival across the spectrum of pulmonary vascular disease
AR Hemnes, JA Leopold, MK Radeva, GJ Beck, A Abidov, MA Aldred, ...
Journal of the American College of Cardiology 80 (7), 697-718, 2022
Mandater: US National Institutes of Health, American Heart Association
Metabolic and functional evaluation of the heart and lungs in pulmonary hypertension by gated 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography
D Saygin, KB Highland, S Farha, M Park, J Sharp, EC Roach, WHW Tang, ...
Pulmonary circulation 7 (2), 428-438, 2017
Mandater: US National Institutes of Health
Management of pulmonary arterial hypertension in patients with systemic sclerosis
S Almaaitah, KB Highland, AR Tonelli
Integrated Blood Pressure Control, 15-29, 2020
Mandater: US National Institutes of Health
The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects
GS Bogatkevich, KB Highland, T Akter, RM Silver
Pulmonary medicine 2012, 2012
Mandater: US National Institutes of Health
Safety and Tolerability of Thrombin Inhibition in Scleroderma‐Associated Interstitial Lung Disease
RM Silver, DA Wilson, T Akter, I Atanelishvili, JT Huggins, K Kajdasz, ...
ACR open rheumatology 1 (7), 403-411, 2019
Mandater: US National Institutes of Health
Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE
NH Kim, AR Hemnes, MM Chakinala, KB Highland, KM Chin, ...
The Journal of Heart and Lung Transplantation 40 (4), 279-288, 2021
Mandater: US National Institutes of Health
Delphi consensus recommendations on management of dosing, adverse events, and comorbidities in the treatment of idiopathic pulmonary fibrosis with nintedanib
F Rahaghi, JA Belperio, J Fitzgerald, M Gulati, R Hallowell, KB Highland, ...
Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine …, 2021
Mandater: US National Institutes of Health
Executive summary: monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians …
RP Baughman, KC Meyer, I Nathanson, L Angel, SM Bhorade, KM Chan, ...
Chest 142 (5), 1284-1288, 2012
Mandater: US National Institutes of Health
Rationale for anticoagulant therapy of pulmonary fibrosis
GS Bogatkevich, PJ Nietert, RM Silver, KB Highland
American journal of respiratory and critical care medicine 189 (3), 362-363, 2014
Mandater: US National Institutes of Health
Evaluation of physical health status beyond daily step count using a wearable activity sensor
Z Xu, N Zahradka, S Ip, A Koneshloo, RT Roemmich, S Sehgal, ...
npj Digital Medicine 5 (1), 164, 2022
Mandater: US National Institutes of Health
Informasjon om publisering og finansiering fastsettes automatisk av et datamaskinprogram